Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity ...